The use of liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis: Results of a pilot randomized, double‐blind, placebo‐controlled trial

Aim To investigate the feasibility and acceptability of using liraglutide 3.0 mg daily in the management of overweight and obesity in people with schizophrenia, schizoaffective disorder and first episode psychosis. Materials and Methods A double‐blind, randomized, placebo‐controlled pilot trial took...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Diabetes, obesity & metabolism obesity & metabolism, 2021-06, Vol.23 (6), p.1262-1271
Hauptverfasser:	Whicher, Clare A., Price, Hermione C., Phiri, Peter, Rathod, Shanaya, Barnard‐Kelly, Katharine, Ngianga, Kandala, Thorne, Kerensa, Asher, Carolyn, Peveler, Robert C., McCarthy, Joanne, Holt, Richard I. G.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antidiabetics Antipsychotics Body mass index Body weight Dosage Double-Blind Method Double-blind studies feasibility Humans Liraglutide Mental disorders Obesity Obesity - complications Obesity - drug therapy Overweight Overweight - complications pilot Pilot Projects Placebos Psychosis Psychotic Disorders - complications Psychotic Disorders - drug therapy Psychotic Disorders - epidemiology Schizoaffective disorder Schizophrenia Schizophrenia - complications Schizophrenia - drug therapy Schizophrenia - epidemiology severe mental illness Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!